title: CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
abstract: Diazepam-binding inhibitor (DBI) is a 9-kD neuropeptide that interacts with the benzodiazepine (BZD) binding sites of the neuronal gamma-aminobutyric acid type A (GABAA) receptor and with the glial mitochondrial BZD receptor (MBR). We explored the involvement of CSF DBI-LI in schizophrenia, based on the potential role of GABA in the negative symptoms associated with schizophrenia, the relationship of its receptors with dopamine and norepinephrine release, and the proposed therapeutic efficacy of BZDs in schizophrenia. Clinical data, CSF DBI-LI and CSF monoamine measures were obtained in 65 drug-free male chronic (DSM-IIIR) schizophrenic patients, 53 of whom were also tested prior to haloperidol withdrawal. Following haloperidol withdrawal, CSF DBI-LI increased significantly. Drug-free CSF DBI-LI did not correlate with CSF monoamines. CSF DBI-LI was significantly higher in paranoid compared to chronic undifferentiated schizophrenic patients. The data suggest that DBI may have a symptom modulatory rather than an etiological role in schizophrenia.
authors.affiliation: Highland Drive VAMC, Pittsburgh, PA 15206.
authors.forename: D P
authors.initials: DP
authors.lastname: van Kammen
authors.forename: A
authors.initials: A
authors.lastname: Guidotti
authors.forename: M E
authors.initials: ME
authors.lastname: Kelley
authors.forename: J
authors.initials: J
authors.lastname: Gurklis
authors.forename: P
authors.initials: P
authors.lastname: Guarneri
authors.forename: M W
authors.initials: MW
authors.lastname: Gilbertson
authors.forename: J K
authors.initials: JK
authors.lastname: Yao
authors.forename: J
authors.initials: J
authors.lastname: Peters
authors.forename: E
authors.initials: E
authors.lastname: Costa
mesh_terms: D000328:Adult; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002352:Carrier Proteins / Q000134:cerebrospinal fluid*; D026261:Diazepam Binding Inhibitor; D004298:Dopamine / Q000502:physiology; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000502:physiology; D011569:Psychiatric Status Rating Scales; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013375:Substance Withdrawal Syndrome / Q000134:cerebrospinal fluid; D005680:gamma-Aminobutyric Acid / Q000502:physiology
chemical_list: D002352:Carrier Proteins; D026261:Diazepam Binding Inhibitor; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine